HER2-Positive Early Breast Cancer Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

HER2-Positive Early Breast Cancer Epidemiology Forecast Report Coverage

Expert Market Research's “HER2-Positive Early Breast Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of HER2-positive early breast cancer. It projects the future incidence and prevalence rates of HER2-positive early breast cancer cases across various populations. The study covers age, gender, and type as major determinants of the HER2-positive early breast cancer population. The report highlights patterns in the prevalence of HER2-positive early breast cancer over time and projects future trends based on multiple variables.

HER2-Positive Early Breast Cancer Understanding: Disease Overview

HER2-positive early breast cancer is a subtype of breast cancer defined by the overexpression or amplification of the HER2 (human epidermal growth factor receptor 2) gene. HER2 is a protein that promotes the growth and division of breast cancer cells. When present in excessive quantities, it drives more aggressive tumor behavior. Early-stage disease refers to breast cancer that has not yet spread beyond the breast and nearby lymph nodes, typically classified as stage I, II, or III. While HER2-positive breast cancers tend to be more aggressive than HER2-negative subtypes, they are also highly responsive to targeted therapies such as trastuzumab, pertuzumab, and antibody-drug conjugates. HER2-positive breast cancer is more commonly diagnosed in younger, premenopausal women and is associated with higher histological grade tumors.

HER2-Positive Early Breast Cancer Epidemiology Perspective

The HER2-positive early breast cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for HER2-positive early breast cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for HER2-positive early breast cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the National Cancer Institute’s SEER program, the HR+/HER2− breast cancer subtype is the most prevalent, with an age-adjusted incidence rate of 91.3 new cases per 100,000 women (2018–2022). This rate is more than six times higher than HR−/HER2− (13.9) and HR+/HER2+ (12.3), and over 17 times higher than HR−/HER2+ (5.1) per 100,000 women, based on age-adjusted estimates.
• As per the Chiara Tommasi et al., 2024, HER2-positive breast cancers represent approximately 14% of all female breast cancer cases. The 5-year relative survival rate for patients with HR+/HER2+ breast cancer is 91%, while for HR-/HER2+ it stands at 83.6%.
• According to Guorong He et al., 2024, primary breast cancer in individuals under 20 occurs at 2–8 per 100,000 and shows distinct features from adults. A SEER-based cohort of 115 patients identified stage as an independent survival predictor and developed a nomogram to estimate survival.
• As per Sherlissa Ali-Thompson et al., 2024, breast cancer accounts for 12.5% of new cancer cases globally with 6.9% mortality. HER2-positive breast cancer constitutes approximately 10%–15% of cases and demonstrates aggressive growth, higher recurrence, metastasis risk, and significant implications for targeted treatment and prognosis.

Read more about this report - Request a Free Sample

Country-wise HER2-Positive Early Breast Cancer Epidemiology

The HER2-positive early breast cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

According to the American Cancer Society, regional variations in HER2-positive early breast cancer reflect differences in screening, access to care, and population characteristics. In the United States, approximately 1 in 8 women (13.19%) will develop invasive breast cancer, with HR−/HER2+ tumors comprising about 3%–6% of cases across racial groups. Incidence rates range from 104–108 per 100,000 among Hispanic and Asian American/Pacific Islander women to 138 per 100,000 in White women, while mortality is highest in Black women (27 per 100,000). In India, HER2-positive prevalence ranges from 11% to 17%, according to Shona Nag et al. (2024), reflecting distinct regional epidemiological patterns.

HER2-Positive Early Breast Cancer: Treatment Overview

The treatment landscape for HER2-positive early breast cancer has evolved significantly since the introduction of trastuzumab (Herceptin) in the early 2000s. Current standard-of-care for early-stage HER2-positive disease typically involves a combination of surgery, chemotherapy, and HER2-targeted therapy. Neoadjuvant therapy (treatment before surgery) using trastuzumab and pertuzumab with chemotherapy has become standard for patients with higher-risk disease. For patients with residual disease after neoadjuvant treatment, adjuvant trastuzumab emtansine (T-DM1) has demonstrated significant benefit in reducing recurrence risk. These advancements signal a potential paradigm shift in curative-intent treatment strategies for HER2-positive early breast cancer.

Key Questions Answered

• What are the key findings of HER2-positive early breast cancer epidemiology in the 8 major markets?
• What will be the total number of patients with HER2-positive early breast cancer across the 8 major markets during the forecast period?
• What was the country-wise HER2-positive early breast cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of HER2-positive early breast cancer patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of HER2-positive early breast cancer during the forecast period of 2026-2035?
• What are the currently available treatments for HER2-positive early breast cancer?
• What are the disease risks, signs, symptoms, and unmet needs of HER2-positive early breast cancer?

Scope of the HER2-Positive Early Breast Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of HER2-positive early breast cancer based on several factors.
• HER2-positive early breast cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The HER2-positive early breast cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Breast Cancer Drug Pipeline Analysis Report

HER2 Positive Breast Cancer Pipeline Analysis Report

Breast Cancer Treatment Market